ClinicalTrials.gg
CompletedNCT01352221AEGIS-2Updated Oct 30, 2020Results posted

Safety and Efficacy Study of Oral Ferric Iron To Treat Iron Deficiency Anaemia in Quiescent Crohn's Disease (AEGIS-2)

A Phase 3 interventional study of ST10 and Placebo oral capsule in Iron Deficiency Anaemia, Inflammatory Bowel Disease and Crohn's Disease, sponsored by Shield Therapeutics. Completed. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2020-10-30.

Sponsored by Shield Therapeutics · Phase 3, Interventional, and Treatment

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 3
Study type
Interventional
Enrollment
128
Allocation
Randomized
Ages
18 Years and older
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-17

Among 12 studies testing ferric maltol in Anemia, Iron-Deficiency — none open to participants now, none under way, none of them phase 3. ferric maltol · Anemia, Iron-Deficiency.

Enrollment
3rd of 12
128 · median 78
Started
2011
with 1 other
Phase 3
7 of 12
none open now
Registered
2nd of 12
by date
Lead sponsor
7 of 12
Shield Therapeutics

Among the 12 studies testing ferric maltol in Anemia, Iron-Deficiency, this one is the 3rd largest by enrollment, is one of 2 that started in 2011, is one of 7 in phase 3, and was the 2nd registered.

Anemia, Iron-Deficiency

601 studies on the registry are indexed under Anemia, Iron-Deficiency; 96 are open to participants now.

Browse Anemia, Iron-Deficiency studies →

Open to participants now

None of the 12 studies testing ferric maltol in Anemia, Iron-Deficiency is open now. The open studies under Anemia, Iron-Deficiency, anywhere →

About ferric maltol

ferric maltol: first FDA approval 2019 (ACCRUFER), first EMA approval 2016. What it is approved for, and how studies give it, is on its page →

Who these studies take

Of the 55 Anemia, Iron-Deficiency studies recruiting now, 19 (35%) set no upper age limit and 32 (58%) stop at 75 or younger; 16 take children under 18; 17 take healthy volunteers.

This study: 18 Years and older · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Download CSVNarrow it in search →With an account: the 12 studies testing ferric maltol in Anemia, Iron-Deficiency as a file.
02

Study summary

The purpose of this study is to determine whether ST10-021, an oral ferric iron preparation, is safe and effective in the treatment of iron deficiency anaemia (IDA) in subjects with non-active Crohn's Disease (CD).

Read the detailed description

As no curative treatment is currently available for Crohn's Disease (CD), treatment options are restricted to controlling symptoms, maintaining remission and preventing relapse. As such, treatment of iron deficiency anaemia (IDA), a key symptom of the disease, is integral to the medical management of CD. Iron deficiency anaemia in CD is a chronically debilitating disorder which has a significant impact on the quality of life of affected subjects. Characteristic symptoms of IDA include chronic fatigue, headache, and subtle impairment of cognitive function. Up to one third of subjects with CD suffer from recurrent anaemia, with hospitalization required in severe cases. First line standard therapy for mild to moderate IDA in CD is typically oral ferrous products (OFP), however this is often not successful. Many subjects are intolerant and suffer from continuously occurring side effects, occasional exacerbation of inflammatory lesions and failure to correct iron deficiency. Common adverse effects of OFP include nausea, epigastric discomfort and constipation, all of which are dose-related and appear especially evident in subjects with CD.

As compared to oral ferrous iron, oral ferric iron can be administered with improved tolerability and the total dose exposure of unabsorbed iron within the gastrointestinal tract is significantly reduced. In addition, the iron is retained in its chelated form if not absorbed and this may reduce the risk of irritation within the gastrointestinal tract. Clinical studies conducted to date provide preliminary evidence for the therapeutic potential of ST10-021 in patients with IDA in Inflammatory Bowel Disease, including CD.

The purpose of this study is to determine whether ST10-021 is safe and effective in the treatment of IDA in subjects with non-active CD. In an effort to target an underserved population, the study will include only those subjects who have failed OFP in the past, or where OFP cannot be used.

03

Conditions studied

  • Iron Deficiency Anaemia
  • Inflammatory Bowel Disease
  • Crohn's Disease

Keywords

  • iron deficiency
  • anaemia
  • inflammatory bowel disease
  • Crohn's Disease
04

Who can participate

Ages eligible
18 Years and older
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Competency to understand and sign the IEC/IRB approved form prior to any study mandated procedure, and willing/able to comply with study requirements
  • Age ≥ 18 years
  • Current diagnosis of quiescent CD as defined by CDAI score of \< 220
  • Current diagnosis of IDA as defined by ≥ 9.5 g/dl and \<12.0 g/dl for women and ≥ 9.5 g/dl and \<13.0 g/dl for men; ferritin \< 30 µg/l
  • Prior OFP failure as defined per protocol
  • If receiving protocol-allowed must be on stable dose
  • Females of must agree to use a reliable method of

Exclusion criteria

Exclusion Criteria:

  • Anaemia due to any cause other than iron deficiency
  • Intramuscular or intravenous injection or administration of depot iron preparation, blood infusions, or erythropoietin within 3 months
  • Oral iron supplementation use within 1 month
  • Use of with known effect of anaemia induction within 1 month
  • Vitamin B12 or Folic Acid injection/infusion within 4 weeks
  • Untreated Vitamin B-12 or Folic Acid deficiency
  • Known or allergy to ST10-021 or components of the study medication, or for treatment with iron preparations
  • Other chronic or acute inflammatory or infectious diseases
  • Creatinine > 2.0 mg/dl
  • or ALT levels ≥ 5 times the
  • Cardiovascular, liver, renal, hematologic, gastrointestinal, immunologic, endocrine, metabolic, or central nervous system disease that may adversely affect the safety of the subject and/or efficacy of the study drug or severely limit the lifespan of the subject
  • History of within the past 5 years (except in situ removal of basal cell carcinoma)
  • Significant neurologic or psychiatric symptoms resulting in disorientation, memory impairment, or inability to report accurately that might interfere with treatment compliance, study conduct or interpretation of the results
  • Participation in another interventional clinical study within 30 days or during the study
  • Inmates of a psychiatric ward, prison, or other state institution
  • Investigator or any other team member involved directly or indirectly in the conduct of the clinical study
  • Scheduled or expected hospitalization and/or surgery during the course of the study
  • Females who are pregnant or lactating
Terms in these criteria, in plain language(10)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

Hemoglobin (Hb)

The protein in red blood cells that carries oxygen. A low level is anemia, which can cause tiredness and breathlessness. Measured in g/dL or g/L (9 g/dL is 90 g/L).

Immunosuppression

A weakened immune system. It can come from an illness, such as HIV or some blood cancers, or from medicines that turn the immune system down, for example after an organ transplant or for an autoimmune disease; steroids at higher doses count.

Read whether the line is about a condition or about medicines, and which medicines and doses it means.

Childbearing potential

Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).

Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.

Contraception

Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.

Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.

Hypersensitivity

An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.

Contraindication

A reason a treatment, test or procedure should not be given to a particular person, such as an allergy, another illness or a medicine they take.

ALT and AST (liver enzymes)

Two enzymes measured in a routine blood test of the liver. Higher levels can mean the liver is under strain or damaged. SGPT and SGOT are older names for ALT and AST.

Criteria usually give a limit as a multiple of the upper limit of normal (ULN), often higher when cancer has spread to the liver.

ULN (upper limit of normal)

The top of the normal range for a blood test, as set by the laboratory that runs it. Each lab prints its own range next to your result.

“≤ 2.5 × ULN” means the result can be up to two and a half times that top value.

Cancer (malignancy)

Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.

Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.

05

Study design

Phase
Phase 3
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Double (Participant, Investigator)
Enrollment
128 participants (actual)

Study arms

  • Experimental
    ST10

    ST10 (Ferric Maltol) 30mg capsules, taken orally twice a day

    Drug: ST10

  • Placebo comparator
    Placebo

    Matching placebo capsules for ST10 (Ferric Maltol), taken orally twice a day

    Drug: Placebo oral capsule

Interventions

  • DrugST10

    30 mg capsules to be taken orally twice a day for 12 weeks in double-blind phase

    Also known as: Ferric Trimaltol, Ferric Maltol

  • DrugPlacebo oral capsule

    Matching placebo capsules for ST10 to be taken orally twice a day for 12 weeks in double-blind phase

06

What researchers measure

Primary outcomes

  1. Change in Haemoglobin (Hb) Concentration From Baseline to Week 12 (Full Analysis Set, FAS)

    Primary efficacy endpoint, defined as the change in Hb concentration from Baseline to Week 12. Baseline was defined as the pre-dose Hb concentration measured at the Randomisation Visit (Week 0). Missing Randomisation Hb values were replaced by Screening Hb values, if the randomisation was within the protocol-specified window. Hb concentration (g/dL) was analysed by a central laboratory from blood samples collected at every clinic visit: Screening, Randomisation (Week 0), Weeks 4, 8, 12, 14, 16, 20, 24, 36, 48, 64, Weeks 14 to 64 were open-label. The baseline, absolute concentration and change from baseline in Hb at all post-randomisation visits were listed and summarised by week using descriptive statistics. An analysis of covariance (ANCOVA) was used to analyse the primary endpoint; this included treatment, gender and disease as factors and baseline Hb as a covariate.

    Time frame: Baseline to Week 12 - double-blind phase

Secondary outcomes

  1. Proportion of Subjects That Achieved ≥1 g/dL Change From Baseline in Hb Concentration at Week 12 (Full Analysis Set, FAS)

    Logistic regression analysis of proportion of subjects that achieved ≥1 g/dL change from baseline in Hb concentration at Week 12 in the double-blind phase

    Time frame: Subjects that achieved ≥1 g/dL change from baseline in Hb concentration at Week 12 - double-blind phase

  2. Proportion of Subjects That Achieved ≥2 g/dL Change From Baseline in Hb Concentration at Week 12 (Full Analysis Set, FAS)

    Logistic regression analysis of proportion of subjects that achieved ≥2 g/dL change from baseline in Hb concentration at Week 12 in the double-blind phase

    Time frame: Baseline to Week 12 - double-blind phase

  3. Proportion of Subjects That Achieved Hb Concentration Within Normal Range at Week 12 (Full Analysis Set, FAS)

    Logistic regression analysis of proportion of subjects that achieved Hb concentration within normal range at Week 12 end of double-blind phase

    Time frame: Baseline to Week 12 - double-blind phase

  4. Change in Hb Concentration From Baseline to Week 4 (Full Analysis Set, FAS)

    ANCOVA analysis of the change in Hb concentration from Baseline to Week 4 of the double-blind phase - Full Analysis Set, multiple imputation

    Time frame: Baseline to Week 4 - double-blind phase

  5. Change in Hb Concentration From Baseline to Week 8 (Full Analysis Set, FAS)

    ANCOVA analysis of Change in Hb concentration from Baseline to Week 8 of double-blind phase - FAS, multiple imputation

    Time frame: Baseline to Week 8 - double-blind phase

  6. Change in Haemoglobin Concentration From Baseline to Week 16 (Full Analysis Set, FAS)

    Change in Haemoglobin Concentration from Baseline to Week 16 (FAS), after 12-week double-blind phase and first 4 weeks of open-label ST10 treatment.

    Time frame: Baseline to Week 16 - open-label phase

  7. Change in Haemoglobin Concentration From Baseline to Week 20 (Full Analysis Set, FAS)

    Change in Haemoglobin Concentration from Baseline to Week 20 (FAS), after 12-week double-blind phase and then 8 weeks of open-label ST10 treatment

    Time frame: Baseline to Week 20 - open-label phase

  8. Change in Haemoglobin Concentration From Baseline to Week 24 (Full Analysis Set, FAS)

    Change in Haemoglobin Concentration from Baseline to Week 24 (FAS), after 12-week double-blind phase and then 12 weeks of open-label ST10 treatment

    Time frame: Baseline to Week 24 - open-label phase

  9. Change in Haemoglobin Concentration From Baseline to Week 36 (Full Analysis Set, FAS)

    Change in Haemoglobin Concentration from Baseline to Week 36 (FAS), after 12-week double-blind phase and then 24 weeks of open-label ST10 treatment

    Time frame: Baseline to Week 36 - open-label phase

  10. Change in Haemoglobin Concentration From Baseline to Week 48 (Full Analysis Set, FAS)

    Change in Haemoglobin Concentration from Baseline to Week 48 (FAS), after 12-week double-blind phase and then 36 weeks of open-label ST10 treatment

    Time frame: Baseline to Week 48 - open-label phase

  11. Change in Haemoglobin Concentration From Baseline to Week 64 (Full Analysis Set, FAS)

    Change in Haemoglobin Concentration from Baseline to Week 64 (FAS), after 12-week double-blind phase and then 52 weeks of open-label ST10 treatment

    Time frame: Baseline to Week 64 - open-label phase

  12. Change in Haemoglobin Concentration From Baseline to Week 64 EOS (Full Analysis Set, FAS)

    Change in Haemoglobin Concentration from Baseline to Week 64 EOS (FAS) - Week 64 was re-categorised as Week 64 EOS for those subjects who withdrew from the study early and the 'Week 64' visit was outside the visit window of 64 weeks ± 2 days

    Time frame: Baseline to Week 64 EOS - open-label phase

  13. Proportion of Subjects That Achieved Haemoglobin Concentration Within Normal Range at Week 16 (Full Analysis Set, FAS)

    Proportion of subjects that achieved Haemoglobin Concentration within normal range at Week 16 (Full Analysis Set), after 12-week double-blind phase and first 4 weeks of open-label ST10 treatment

    Time frame: Baseline to Week 16 - open-label phase

  14. Proportion of Subjects That Achieved Haemoglobin Concentration Within Normal Range at Week 36 (Full Analysis Set, FAS)

    Proportion of subjects that achieved Haemoglobin Concentration within normal range at Week 36 (Full Analysis Set), after 12-week double-blind phase and 24 weeks of open-label ST10 treatment

    Time frame: Baseline to Week 36 - open-label phase

  15. Proportion of Subjects That Achieved Haemoglobin Concentration Within Normal Range at Week 64 (Full Analysis Set, FAS)

    Proportion of subjects that achieved Haemoglobin Concentration within normal range at Week 64 (Full Analysis Set), after 12-week double-blind phase and 52 weeks of open-label ST10 treatment

    Time frame: Baseline to Week 64 - open-label phase

  16. Change in Haemoglobin Concentration From Baseline to Week 12 (Per Protocol Analysis Set, PPAS)

    ANCOVA sensitivity analysis of the Primary efficacy endpoint analysis on the PPAS - Change in Haemoglobin Concentration from Baseline to Week 12

    Time frame: Baseline to Week 12 - double-blind phase

  17. Change in Haemoglobin Concentration From Baseline to Week 12 (Full Analysis Set [FAS] LOCF)

    ANCOVA sensitivity analysis of the Primary efficacy endpoint analysis on the FAS LOCF - Change in Haemoglobin Concentration from Baseline to Week 12

    Time frame: Baseline to Week 12 - double-blind phase

Other outcomes

  1. Change in Serum Ferritin Concentration From Baseline to Week 12 (Full Analysis Set, FAS)

    Change in serum Ferritin concentration from Baseline to Week 12 (Full Analysis Set), after 12-week double-blind phase

    Time frame: Baseline to Week 12 - double-blind phase

  2. Change in Serum TSAT% From Baseline to Week 12 (Full Analysis Set, FAS)

    Change in serum TSAT% from Baseline to Week 12 (FAS), after 12-week double-blind phase

    Time frame: Baseline to Week 12 - double-blind phase

  3. Change in Serum Ferritin Concentration From Baseline to Week 64 (Full Analysis Set, FAS)

    Change in serum Ferritin concentration from Baseline to Week 64 (FAS), after 12-week double-blind phase and 52 weeks open-label ST10 treatment

    Time frame: Baseline to Week 64 - open-label phase

  4. Change in Serum TSAT% From Baseline to Week 64 (Full Analysis Set, FAS)

    Change in serum TSAT% from Baseline to Week 64 (Full Analysis Set), after 12-week double-blind phase and 52 weeks open-label ST10 treatment

    Time frame: Baseline to Week 64 - open-label phase

  5. Irritable Bowel Disease Questionnaire (IBDQ) Score at Week 12 (Full Analysis Set, FAS)

    Irritable Bowel Disease Questionnaire (IBDQ) score at Week 12 (FAS), end of double-blind phase. The IBDQ was developed as an activity index for determining the effect of Crohn's disease symptoms on perceived quality of life. It is a 32-item questionnaire with four dimensions: bowel function, emotional status, systemic symptoms and social function. Total IBDQ score ranges from 32 to 224, with higher scores indicating better quality of life. The score of patients in remission usually is between 170 and 190.

    Time frame: Week 12 - double-blind phase

  6. Irritable Bowel Disease Questionnaire (IBDQ) Score at Week 64 (Full Analysis Set, FAS)

    Irritable Bowel Disease Questionnaire (IBDQ) score at Week 64 (FAS), after 12-week double-blind phase and 52 weeks of open-label ST10 treatment. The IBDQ was developed as an activity index for determining the effect of Crohn's disease symptoms on perceived quality of life. It is a 32-item questionnaire with four dimensions: bowel function, emotional status, systemic symptoms and social function. Total IBDQ score ranges from 32 to 224, with higher scores indicating better quality of life. The score of patients in remission usually is between 170 and 190.

    Time frame: Week 64 - open-label phase

  7. Change From Baseline in Crohn's Disease Activity Index (CDAI) Score at Week 12 (Full Analysis Set, FAS)

    Change from baseline (randomisation) in Crohn's Disease Activity Index (CDAI) score at Week 12 (FAS), end of double-blind phase (in subjects with CD). The CDAI is a research tool used to quantify the symptoms of patients with Crohn's disease. CDAI score can range from 0 to approximately 600. Traditionally, for clinical trials, clinical remission is defined as a CDAI score \<150, clinical response is a decrease in CDAI score of 70-100. Mildly active Crohn's disease is defined as a CDAI score 150-220, moderate-severe Crohn's is typically a CDAI 220-450, and severe disease is defined as a CDAI \>450.

    Time frame: Baseline to Week 12 - double-blind phase

  8. Change From Baseline in Crohn's Disease Activity Index (CDAI) Score at Week 64 (Full Analysis Set, FAS)

    Change from baseline in Crohn's Disease Activity Index (CDAI) score at Week 64 (FAS), after 12-week double blind phase and 52 weeks open-label ST10 treatment (in participants with CD only). The CDAI is a research tool used to quantify the symptoms of patients with Crohn's disease. CDAI score can range from 0 to approximately 600. Traditionally, for clinical trials, clinical remission is defined as a CDAI score \<150, clinical response is a decrease in CDAI score of 70-100. Mildly active Crohn's disease is defined as a CDAI score 150-220, moderate-severe Crohn's is typically a CDAI 220-450, and severe disease is defined as a CDAI \>450.

    Time frame: Baseline to Week 64 - open-label phase

07

Results

Posted Oct 27, 2017

Participant flow

Potential subjects were selected from the general population attending each centre in UK, DE, AT or HU for routine care of their IBD and anaemia. Individuals interested in participating were invited for the Screening visit in order to assess eligibility. Written informed consent was obtained prior to conducting any study specific assessments

Double-blind Phase
Participant flow — Double-blind Phase
MilestoneST10PlaceboST10 - Open-label Continuation From Active Arm in Double-blindPlacebo Switch to Open-label Extension ST10 Treatment
Started646400
Completed555300
Not completed91100
Withdrew: Adverse event6400
Withdrew: Withdrawal by subject3500
Withdrew: Lost to follow-up0100
Withdrew: Protocol violation0100
Open-label Phase
Participant flow — Open-label Phase
MilestoneST10PlaceboST10 - Open-label Continuation From Active Arm in Double-blindPlacebo Switch to Open-label Extension ST10 Treatment
Started005047
Completed003736
Not completed001311
Withdrew: Physician decision0021
Withdrew: Pregnancy0010
Withdrew: Adverse event0084
Withdrew: Withdrawal by subject0016
Withdrew: Worsening of ibd0010

Outcome measures

PrimaryChange in Haemoglobin (Hb) Concentration From Baseline to Week 12 (Full Analysis Set, FAS)

Primary efficacy endpoint, defined as the change in Hb concentration from Baseline to Week 12. Baseline was defined as the pre-dose Hb concentration measured at the Randomisation Visit (Week 0). Missing Randomisation Hb values were replaced by Screening Hb values, if the randomisation was within the protocol-specified window. Hb concentration (g/dL) was analysed by a central laboratory from blood samples collected at every clinic visit: Screening, Randomisation (Week 0), Weeks 4, 8, 12, 14, 16, 20, 24, 36, 48, 64, Weeks 14 to 64 were open-label. The baseline, absolute concentration and change from baseline in Hb at all post-randomisation visits were listed and summarised by week using descriptive statistics. An analysis of covariance (ANCOVA) was used to analyse the primary endpoint; this included treatment, gender and disease as factors and baseline Hb as a covariate.

Time frame:
Baseline to Week 12 - double-blind phase
Reported as:
Mean · g/dL
Change in Haemoglobin (Hb) Concentration From Baseline to Week 12 (Full Analysis Set, FAS)
g/dLST10Placebo
Change in Haemoglobin (Hb) Concentration From Baseline to Week 12 (Full Analysis Set, FAS)2.26 ± 1.1840.01 ± 0.764
Statistical analysis
  • ST10 vs Placebo · ANCOVA · p = < 0.0001 · Mean difference (final values): 2.18
SecondaryProportion of Subjects That Achieved ≥1 g/dL Change From Baseline in Hb Concentration at Week 12 (Full Analysis Set, FAS)

Logistic regression analysis of proportion of subjects that achieved ≥1 g/dL change from baseline in Hb concentration at Week 12 in the double-blind phase

Time frame:
Subjects that achieved ≥1 g/dL change from baseline in Hb concentration at Week 12 - double-blind phase
Reported as:
Count of participants · Participants
Proportion of Subjects That Achieved ≥1 g/dL Change From Baseline in Hb Concentration at Week 12 (Full Analysis Set, FAS)
ParticipantsST10Placebo
Yes507
No1457
SecondaryProportion of Subjects That Achieved ≥2 g/dL Change From Baseline in Hb Concentration at Week 12 (Full Analysis Set, FAS)

Logistic regression analysis of proportion of subjects that achieved ≥2 g/dL change from baseline in Hb concentration at Week 12 in the double-blind phase

Time frame:
Baseline to Week 12 - double-blind phase
Reported as:
Count of participants · Participants
Proportion of Subjects That Achieved ≥2 g/dL Change From Baseline in Hb Concentration at Week 12 (Full Analysis Set, FAS)
ParticipantsST10Placebo
Yes360
No2864
SecondaryProportion of Subjects That Achieved Hb Concentration Within Normal Range at Week 12 (Full Analysis Set, FAS)

Logistic regression analysis of proportion of subjects that achieved Hb concentration within normal range at Week 12 end of double-blind phase

Time frame:
Baseline to Week 12 - double-blind phase
Reported as:
Count of participants · Participants
Proportion of Subjects That Achieved Hb Concentration Within Normal Range at Week 12 (Full Analysis Set, FAS)
ParticipantsST10Placebo
Yes428
No2256
SecondaryChange in Hb Concentration From Baseline to Week 4 (Full Analysis Set, FAS)

ANCOVA analysis of the change in Hb concentration from Baseline to Week 4 of the double-blind phase - Full Analysis Set, multiple imputation

Time frame:
Baseline to Week 4 - double-blind phase
Reported as:
Mean · g/dL
Change in Hb Concentration From Baseline to Week 4 (Full Analysis Set, FAS)
g/dLST10Placebo
Change in Hb Concentration From Baseline to Week 4 (Full Analysis Set, FAS)1.08 ± 0.6760 ± 0.67
Statistical analysis
  • ST10 vs Placebo · ANCOVA · p = < 0.0001 · Mean difference (final values): 1.04
SecondaryChange in Hb Concentration From Baseline to Week 8 (Full Analysis Set, FAS)

ANCOVA analysis of Change in Hb concentration from Baseline to Week 8 of double-blind phase - FAS, multiple imputation

Time frame:
Baseline to Week 8 - double-blind phase
Reported as:
Mean · g/dL
Change in Hb Concentration From Baseline to Week 8 (Full Analysis Set, FAS)
g/dLST10Placebo
Change in Hb Concentration From Baseline to Week 8 (Full Analysis Set, FAS)1.79 ± 1.0370.04 ± 0.722
Statistical analysis
  • ST10 vs Placebo · ANCOVA · p = < 0.0001 (ANCOVA analysis of Change in Hb concentration from Baseline to Week 8 of double-blind phase - FAS, multiple imputation) · Mean difference (final values): 1.73
SecondaryChange in Haemoglobin Concentration From Baseline to Week 16 (Full Analysis Set, FAS)

Change in Haemoglobin Concentration from Baseline to Week 16 (FAS), after 12-week double-blind phase and first 4 weeks of open-label ST10 treatment.

Time frame:
Baseline to Week 16 - open-label phase
Reported as:
Mean · g/dL
Change in Haemoglobin Concentration From Baseline to Week 16 (Full Analysis Set, FAS)
g/dLST10 - Open-label Continuation From Active Arm in Double-blindPlacebo Switch to Open-label Extension ST10 Treatment
Change in Haemoglobin Concentration From Baseline to Week 16 (Full Analysis Set, FAS)2.34 ± 1.2811.04 ± 1.023
SecondaryChange in Haemoglobin Concentration From Baseline to Week 20 (Full Analysis Set, FAS)

Change in Haemoglobin Concentration from Baseline to Week 20 (FAS), after 12-week double-blind phase and then 8 weeks of open-label ST10 treatment

Time frame:
Baseline to Week 20 - open-label phase
Reported as:
Mean · g/dL
Change in Haemoglobin Concentration From Baseline to Week 20 (Full Analysis Set, FAS)
g/dLST10 - Open-label Continuation From Active Arm in Double-blindPlacebo Switch to Open-label Extension ST10 Treatment
Change in Haemoglobin Concentration From Baseline to Week 20 (Full Analysis Set, FAS)2.45 ± 1.2131.46 ± 1.056
SecondaryChange in Haemoglobin Concentration From Baseline to Week 24 (Full Analysis Set, FAS)

Change in Haemoglobin Concentration from Baseline to Week 24 (FAS), after 12-week double-blind phase and then 12 weeks of open-label ST10 treatment

Time frame:
Baseline to Week 24 - open-label phase
Reported as:
Mean · g/dL
Change in Haemoglobin Concentration From Baseline to Week 24 (Full Analysis Set, FAS)
g/dLST10 - Open-label Continuation From Active Arm in Double-blindPlacebo Switch to Open-label Extension ST10 Treatment
Change in Haemoglobin Concentration From Baseline to Week 24 (Full Analysis Set, FAS)2.68 ± 1.1271.87 ± 1.195
SecondaryChange in Haemoglobin Concentration From Baseline to Week 36 (Full Analysis Set, FAS)

Change in Haemoglobin Concentration from Baseline to Week 36 (FAS), after 12-week double-blind phase and then 24 weeks of open-label ST10 treatment

Time frame:
Baseline to Week 36 - open-label phase
Reported as:
Mean · g/dL
Change in Haemoglobin Concentration From Baseline to Week 36 (Full Analysis Set, FAS)
g/dLST10 - Open-label Continuation From Active Arm in Double-blindPlacebo Switch to Open-label Extension ST10 Treatment
Change in Haemoglobin Concentration From Baseline to Week 36 (Full Analysis Set, FAS)2.85 ± 1.2272.17 ± 1.048
SecondaryChange in Haemoglobin Concentration From Baseline to Week 48 (Full Analysis Set, FAS)

Change in Haemoglobin Concentration from Baseline to Week 48 (FAS), after 12-week double-blind phase and then 36 weeks of open-label ST10 treatment

Time frame:
Baseline to Week 48 - open-label phase
Reported as:
Mean · g/dL
Change in Haemoglobin Concentration From Baseline to Week 48 (Full Analysis Set, FAS)
g/dLST10 - Open-label Continuation From Active Arm in Double-blindPlacebo Switch to Open-label Extension ST10 Treatment
Change in Haemoglobin Concentration From Baseline to Week 48 (Full Analysis Set, FAS)3.09 ± 1.3392.0 ± 1.191
SecondaryChange in Haemoglobin Concentration From Baseline to Week 64 (Full Analysis Set, FAS)

Change in Haemoglobin Concentration from Baseline to Week 64 (FAS), after 12-week double-blind phase and then 52 weeks of open-label ST10 treatment

Time frame:
Baseline to Week 64 - open-label phase
Reported as:
Mean · g/dL
Change in Haemoglobin Concentration From Baseline to Week 64 (Full Analysis Set, FAS)
g/dLST10 - Open-label Continuation From Active Arm in Double-blindPlacebo Switch to Open-label Extension ST10 Treatment
Change in Haemoglobin Concentration From Baseline to Week 64 (Full Analysis Set, FAS)3.07 ± 1.4572.19 ± 1.605
SecondaryChange in Haemoglobin Concentration From Baseline to Week 64 EOS (Full Analysis Set, FAS)

Change in Haemoglobin Concentration from Baseline to Week 64 EOS (FAS) - Week 64 was re-categorised as Week 64 EOS for those subjects who withdrew from the study early and the 'Week 64' visit was outside the visit window of 64 weeks ± 2 days

Time frame:
Baseline to Week 64 EOS - open-label phase
Reported as:
Mean · g/dL
Change in Haemoglobin Concentration From Baseline to Week 64 EOS (Full Analysis Set, FAS)
g/dLST10 - Open-label Continuation From Active Arm in Double-blindPlacebo Switch to Open-label Extension ST10 Treatment
Change in Haemoglobin Concentration From Baseline to Week 64 EOS (Full Analysis Set, FAS)1.32 ± 1.7130.52 ± 1.417
SecondaryProportion of Subjects That Achieved Haemoglobin Concentration Within Normal Range at Week 16 (Full Analysis Set, FAS)

Proportion of subjects that achieved Haemoglobin Concentration within normal range at Week 16 (Full Analysis Set), after 12-week double-blind phase and first 4 weeks of open-label ST10 treatment

Time frame:
Baseline to Week 16 - open-label phase
Reported as:
Count of participants · Participants
Proportion of Subjects That Achieved Haemoglobin Concentration Within Normal Range at Week 16 (Full Analysis Set, FAS)
ParticipantsST10 - Open-label Continuation From Active Arm in Double-blindPlacebo Switch to Open-label Extension ST10 Treatment
Yes3617
No1028
SecondaryProportion of Subjects That Achieved Haemoglobin Concentration Within Normal Range at Week 36 (Full Analysis Set, FAS)

Proportion of subjects that achieved Haemoglobin Concentration within normal range at Week 36 (Full Analysis Set), after 12-week double-blind phase and 24 weeks of open-label ST10 treatment

Time frame:
Baseline to Week 36 - open-label phase
Reported as:
Count of participants · Participants
Proportion of Subjects That Achieved Haemoglobin Concentration Within Normal Range at Week 36 (Full Analysis Set, FAS)
ParticipantsST10 - Open-label Continuation From Active Arm in Double-blindPlacebo Switch to Open-label Extension ST10 Treatment
Yes3529
No67
SecondaryProportion of Subjects That Achieved Haemoglobin Concentration Within Normal Range at Week 64 (Full Analysis Set, FAS)

Proportion of subjects that achieved Haemoglobin Concentration within normal range at Week 64 (Full Analysis Set), after 12-week double-blind phase and 52 weeks of open-label ST10 treatment

Time frame:
Baseline to Week 64 - open-label phase
Reported as:
Count of participants · Participants
Proportion of Subjects That Achieved Haemoglobin Concentration Within Normal Range at Week 64 (Full Analysis Set, FAS)
ParticipantsST10 - Open-label Continuation From Active Arm in Double-blindPlacebo Switch to Open-label Extension ST10 Treatment
Yes3130
No56
SecondaryChange in Haemoglobin Concentration From Baseline to Week 12 (Per Protocol Analysis Set, PPAS)

ANCOVA sensitivity analysis of the Primary efficacy endpoint analysis on the PPAS - Change in Haemoglobin Concentration from Baseline to Week 12

Time frame:
Baseline to Week 12 - double-blind phase
Reported as:
Mean · g/dL
Change in Haemoglobin Concentration From Baseline to Week 12 (Per Protocol Analysis Set, PPAS)
g/dLST10Placebo
Change in Haemoglobin Concentration From Baseline to Week 12 (Per Protocol Analysis Set, PPAS)2.23 ± 0.130.05 ± 0.13
Statistical analysis
  • ST10 vs Placebo · ANCOVA · p = < 0.0001 · Mean difference (final values): 2.18
SecondaryChange in Haemoglobin Concentration From Baseline to Week 12 (Full Analysis Set [FAS] LOCF)

ANCOVA sensitivity analysis of the Primary efficacy endpoint analysis on the FAS LOCF - Change in Haemoglobin Concentration from Baseline to Week 12

Time frame:
Baseline to Week 12 - double-blind phase
Reported as:
Mean · g/dL
Change in Haemoglobin Concentration From Baseline to Week 12 (Full Analysis Set [FAS] LOCF)
g/dLST10Placebo
Change in Haemoglobin Concentration From Baseline to Week 12 (Full Analysis Set [FAS] LOCF)2.11 ± 0.12-0.03 ± 0.12
Statistical analysis
  • ST10 vs Placebo · ANCOVA · p = < 0.0001 · Mean difference (final values): 2.15
Other pre-specifiedChange in Serum Ferritin Concentration From Baseline to Week 12 (Full Analysis Set, FAS)

Change in serum Ferritin concentration from Baseline to Week 12 (Full Analysis Set), after 12-week double-blind phase

Time frame:
Baseline to Week 12 - double-blind phase
Reported as:
Mean · μg/dL
Change in Serum Ferritin Concentration From Baseline to Week 12 (Full Analysis Set, FAS)
μg/dLST10Placebo
Change in Serum Ferritin Concentration From Baseline to Week 12 (Full Analysis Set, FAS)17.3 ± 28.31.2 ± 7.85
Other pre-specifiedChange in Serum TSAT% From Baseline to Week 12 (Full Analysis Set, FAS)

Change in serum TSAT% from Baseline to Week 12 (FAS), after 12-week double-blind phase

Time frame:
Baseline to Week 12 - double-blind phase
Reported as:
Mean · percent
Change in Serum TSAT% From Baseline to Week 12 (Full Analysis Set, FAS)
percentST10Placebo
Change in Serum TSAT% From Baseline to Week 12 (Full Analysis Set, FAS)18.0 ± 20.17-0.4 ± 7.82
Other pre-specifiedChange in Serum Ferritin Concentration From Baseline to Week 64 (Full Analysis Set, FAS)

Change in serum Ferritin concentration from Baseline to Week 64 (FAS), after 12-week double-blind phase and 52 weeks open-label ST10 treatment

Time frame:
Baseline to Week 64 - open-label phase
Reported as:
Mean · μg/dL
Change in Serum Ferritin Concentration From Baseline to Week 64 (Full Analysis Set, FAS)
μg/dLST10 - Open-label Continuation From Active Arm in Double-blindPlacebo Switch to Open-label Extension ST10 Treatment
Change in Serum Ferritin Concentration From Baseline to Week 64 (Full Analysis Set, FAS)60.4 ± 93.3536.6 ± 46.8
Other pre-specifiedChange in Serum TSAT% From Baseline to Week 64 (Full Analysis Set, FAS)

Change in serum TSAT% from Baseline to Week 64 (Full Analysis Set), after 12-week double-blind phase and 52 weeks open-label ST10 treatment

Time frame:
Baseline to Week 64 - open-label phase
Reported as:
Mean · percent
Change in Serum TSAT% From Baseline to Week 64 (Full Analysis Set, FAS)
percentST10 - Open-label Continuation From Active Arm in Double-blindPlacebo Switch to Open-label Extension ST10 Treatment
Change in Serum TSAT% From Baseline to Week 64 (Full Analysis Set, FAS)18.8 ± 12.4617.7 ± 16.2
Other pre-specifiedIrritable Bowel Disease Questionnaire (IBDQ) Score at Week 12 (Full Analysis Set, FAS)

Irritable Bowel Disease Questionnaire (IBDQ) score at Week 12 (FAS), end of double-blind phase. The IBDQ was developed as an activity index for determining the effect of Crohn's disease symptoms on perceived quality of life. It is a 32-item questionnaire with four dimensions: bowel function, emotional status, systemic symptoms and social function. Total IBDQ score ranges from 32 to 224, with higher scores indicating better quality of life. The score of patients in remission usually is between 170 and 190.

Time frame:
Week 12 - double-blind phase
Reported as:
Mean · score on a scale
Irritable Bowel Disease Questionnaire (IBDQ) Score at Week 12 (Full Analysis Set, FAS)
score on a scaleST10Placebo
Irritable Bowel Disease Questionnaire (IBDQ) Score at Week 12 (Full Analysis Set, FAS)178.3 ± 32.36176.3 ± 31.5
Other pre-specifiedIrritable Bowel Disease Questionnaire (IBDQ) Score at Week 64 (Full Analysis Set, FAS)

Irritable Bowel Disease Questionnaire (IBDQ) score at Week 64 (FAS), after 12-week double-blind phase and 52 weeks of open-label ST10 treatment. The IBDQ was developed as an activity index for determining the effect of Crohn's disease symptoms on perceived quality of life. It is a 32-item questionnaire with four dimensions: bowel function, emotional status, systemic symptoms and social function. Total IBDQ score ranges from 32 to 224, with higher scores indicating better quality of life. The score of patients in remission usually is between 170 and 190.

Time frame:
Week 64 - open-label phase
Reported as:
Mean · score on a scale
Irritable Bowel Disease Questionnaire (IBDQ) Score at Week 64 (Full Analysis Set, FAS)
score on a scaleST10 - Open-label Continuation From Active Arm in Double-blindPlacebo Switch to Open-label Extension ST10 Treatment
Irritable Bowel Disease Questionnaire (IBDQ) Score at Week 64 (Full Analysis Set, FAS)180.7 ± 30.14177.2 ± 36.97
Other pre-specifiedChange From Baseline in Crohn's Disease Activity Index (CDAI) Score at Week 12 (Full Analysis Set, FAS)

Change from baseline (randomisation) in Crohn's Disease Activity Index (CDAI) score at Week 12 (FAS), end of double-blind phase (in subjects with CD). The CDAI is a research tool used to quantify the symptoms of patients with Crohn's disease. CDAI score can range from 0 to approximately 600. Traditionally, for clinical trials, clinical remission is defined as a CDAI score \<150, clinical response is a decrease in CDAI score of 70-100. Mildly active Crohn's disease is defined as a CDAI score 150-220, moderate-severe Crohn's is typically a CDAI 220-450, and severe disease is defined as a CDAI \>450.

Time frame:
Baseline to Week 12 - double-blind phase
Reported as:
Median · score on a scale
Change From Baseline in Crohn's Disease Activity Index (CDAI) Score at Week 12 (Full Analysis Set, FAS)
score on a scaleST10Placebo
Change From Baseline in Crohn's Disease Activity Index (CDAI) Score at Week 12 (Full Analysis Set, FAS)-24 (-151 to 49)12.5 (-90 to 124)
Other pre-specifiedChange From Baseline in Crohn's Disease Activity Index (CDAI) Score at Week 64 (Full Analysis Set, FAS)

Change from baseline in Crohn's Disease Activity Index (CDAI) score at Week 64 (FAS), after 12-week double blind phase and 52 weeks open-label ST10 treatment (in participants with CD only). The CDAI is a research tool used to quantify the symptoms of patients with Crohn's disease. CDAI score can range from 0 to approximately 600. Traditionally, for clinical trials, clinical remission is defined as a CDAI score \<150, clinical response is a decrease in CDAI score of 70-100. Mildly active Crohn's disease is defined as a CDAI score 150-220, moderate-severe Crohn's is typically a CDAI 220-450, and severe disease is defined as a CDAI \>450.

Time frame:
Baseline to Week 64 - open-label phase
Reported as:
Median · score on a scale
Change From Baseline in Crohn's Disease Activity Index (CDAI) Score at Week 64 (Full Analysis Set, FAS)
score on a scaleST10 - Open-label Continuation From Active Arm in Double-blindPlacebo Switch to Open-label Extension ST10 Treatment
Change From Baseline in Crohn's Disease Activity Index (CDAI) Score at Week 64 (Full Analysis Set, FAS)-16.6 (-112 to 54)-1.0 (-99 to 58)

Adverse events

Collected over Adverse events (AEs) were solicited after informed consent and until 4 weeks after the last dose of study drug (at study completion or early termination).. Non-serious events are listed at a 3% frequency threshold.

Adverse event summary by group
GroupDeathsSeriousOther
ST10 - Safety Set, Double-blind Phase0/64 (0%)1/64 (1.6%)39/64 (60.9%)
Placebo - Safety Set, Double-blind Phase0/64 (0%)2/64 (3.1%)46/64 (71.9%)
ST10 Continuation - Safety Set, Open-label Phase0/50 (0%)8/50 (16%)40/50 (80%)
Placebo Switch to ST10 Treatment-Safety Set, Open-label Phase0/47 (0%)2/47 (4.3%)35/47 (74.5%)
Most frequent serious events
Showing 10 of 13
Most frequent serious events
EventST10 - Safety Set, Double-blind PhasePlacebo - Safety Set, Double-blind PhaseST10 Continuation - Safety Set, Open-label PhasePlacebo Switch to ST10 Treatment-Safety Set, Open-label Phase
Abdominal PainGastrointestinal disorders1/640/642/500/47
Angina pectorisCardiac disorders0/640/640/501/47
Pulmonary embolismRespiratory, thoracic and mediastinal disorders0/640/640/501/47
PneumoniaInfections and infestations0/640/640/501/47
Colitis ulcerativeGastrointestinal disorders0/640/641/500/47
Cholesteatoma removalSurgical and medical procedures0/640/641/500/47
HerniaGeneral disorders0/640/641/500/47
Rectal haemorrhageGastrointestinal disorders0/640/641/500/47
Herpes zosterInfections and infestations0/640/641/500/47
PeritonitisInfections and infestations0/640/641/500/47
Most frequent other events
Showing 10 of 31
Most frequent other events
EventST10 - Safety Set, Double-blind PhasePlacebo - Safety Set, Double-blind PhaseST10 Continuation - Safety Set, Open-label PhasePlacebo Switch to ST10 Treatment-Safety Set, Open-label Phase
NasopharyngitisInfections and infestations4/648/6412/508/47
Abdominal painGastrointestinal disorders7/645/642/507/47
Colitis ulcerativeGastrointestinal disorders0/640/644/506/47
DiarrhoeaGastrointestinal disorders5/644/644/506/47
Crohn's diseaseGastrointestinal disorders0/644/642/505/47
Abdominal pain upperGastrointestinal disorders1/643/641/504/47
ArthralgiaMusculoskeletal and connective tissue disorders3/640/644/503/47
ConstipationGastrointestinal disorders5/641/642/501/47
FlatulenceGastrointestinal disorders4/640/643/503/47
NauseaGastrointestinal disorders0/641/642/503/47

Baseline characteristics

Potential subjects were screened for eligibility to participate based on their demographics, medical/surgical history, physical examination, concomitant medications, vital signs, clinical laboratory tests (including pregnancy test for females of child-bearing potential) and current IBD disease status (based on CDAI clinical score). FAS - Safety

Age, Categorical
Age, Categorical(Participants)ST10PlaceboTotal
<=18 years000
Between 18 and 65 years6263125
>=65 years213
Age, Continuous
Age, Continuous(years)ST10PlaceboTotal
Mean40.1 ± 13.5238.5 ± 12.339.2 ± 12.9
Sex: Female, Male
Sex: Female, Male(Participants)ST10PlaceboTotal
Female404383
Male242145
Region of Enrollment
Region of Enrollment(participants)ST10PlaceboTotal
United Kingdom151025
Hungary111526
Germany353267
Austria4610
Duration of Crohn's disease (years)
Duration of Crohn's disease (years)(years)ST10PlaceboTotal
Mean11.25 ± 9.29611.01 ± 8.0911.13 ± 8.6
Time since last IBD flare-up (months)
Time since last IBD flare-up (months)(months)ST10PlaceboTotal
Mean24.8 ± 59.1621.51 ± 38.4623.2 ± 48.4
Time since last OFP dose (months)
Time since last OFP dose (months)(months)ST10PlaceboTotal
Mean36.17 ± 40.133.34 ± 44.0434.76 ± 41.7
Haemoglobin concentration at baseline
Haemoglobin concentration at baseline(g/dL)ST10PlaceboTotal
Mean11 ± 1.0311.1 ± 0.8511.05 ± 0.93

4 further baseline measures are reported on the registry.

08

Study locations

No study locations are listed for this record.

09

References and documents

Publications

  • Gasche C, Ahmad T, Tulassay Z, Baumgart DC, Bokemeyer B, Buning C, Howaldt S, Stallmach A; AEGIS Study Group. Ferric maltol is effective in correcting iron deficiency anemia in patients with inflammatory bowel disease: results from a phase-3 clinical trial program. Inflamm Bowel Dis. 2015 Mar;21(3):579-88. doi: 10.1097/MIB.0000000000000314. PubMed 25545376 ↗
  • Schmidt C, Ahmad T, Tulassay Z, Baumgart DC, Bokemeyer B, Howaldt S, Stallmach A, Buning C; AEGIS Study Group. Ferric maltol therapy for iron deficiency anaemia in patients with inflammatory bowel disease: long-term extension data from a Phase 3 study. Aliment Pharmacol Ther. 2016 Aug;44(3):259-70. doi: 10.1111/apt.13665. Epub 2016 May 29. PubMed 27237709 ↗

Individual participant data

Plan to share: No

10

Timeline

Tracking since Sep 25, 2026
Not marked actual or estimatedDates not marked actual or estimated

The record gives a start of Aug 2011, a primary completion of Oct 2013 and a completion of Oct 2014. It does not say whether these dates are actual or estimated.

Results were first posted in Oct 2017, 4 years after primary completion.

How these figures are worked out, and which studies are left out of them.

Registered
May 10, 2011
First posted
May 11, 2011
Start
Aug 2011
Primary completionActual
Oct 2013
CompletionActual
Oct 2014
Results first posted
Oct 27, 2017
Last update
Oct 30, 2020
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Oct 30, 2020, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
11

Registry details

Key details

Study ID
NCT01352221
Lead sponsor
Shield Therapeutics
Responsible party
Sponsor
First posted
May 11, 2011
Start date
Aug 2011
Primary completion
Oct 2013
Completion
Oct 2014
Results posted
Oct 27, 2017
Last update
Oct 30, 2020

Study contacts

Nicholas Mallard, PhD
study director · Shield Therapeutics

Oversight

Data monitoring committee
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Oct 2020. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Ferric maltol

Start the discussion